Core Viewpoint - Peijia Medical-B (09996.HK) reported a revenue of RMB 353.4 million for the six months ending June 30, 2025, representing a 17.3% increase compared to the same period in 2024, driven by strong sales growth in both transcatheter aortic valve replacement (TAVR) and neurointerventional products [1] Revenue Composition - Revenue composition remained stable, with 45.7% from TAVR-related product sales and 54.3% from neurointerventional product sales, compared to 43.3% and 56.7% respectively in the first half of 2024 [1] TAVR Product Sales - TAVR-related product sales increased by 24.0% year-on-year to RMB 161.6 million, driven by market share gains in China's transcatheter aortic valve market and a shift towards newly launched high-end products [1] - Total implantations exceeded 2,050 units during the reporting period, reflecting an approximate 18.8% year-on-year growth, surpassing market growth [1] Neurointerventional Product Sales - Neurointerventional product sales rose by 12.2% year-on-year to RMB 191.8 million, with key drivers including deeper market penetration of existing products (such as DCwire® microcatheter, Tethys AS® aspiration catheter, and Fastunnel® balloon delivery catheter) and the successful launch of the newly approved YonFlow® flow-directed stent [1]
沛嘉医疗-B(09996.HK)中期业绩：收入同比增17.3% 核心业务板块销售强劲